Latest Breaking News On - Switch endocrine therapy - Page 1 : comparemela.com

Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.

United statesKevin kalinskyRibociclib kisqaliWinship cancer instituteEmory universitySwitch endocrine therapyMaintain trialHormone receptor positive breast cancerHer2 negative breast cancerBreast cancerJournal of clinical oncology